TFRC and early-onset autosomal dominant Alzheimer disease: Myricetin also reduces iron uptake in Caco-2 cells [137] and the iron content in vivo by inhibiting the expression of transferrin receptor 1 (TFR1) in an Alzheimer’s disease mouse model [138].